Summary:
- The U.S. FDA has approved the combination therapy of Welireg (belzutifan) and Lenvima (lenvatinib) for the treatment of advanced renal cell carcinoma (ccRCC) in patients who have previously received PD-1/PD-L1 and VEGF-targeted therapies.
- This approval is based on clinical data demonstrating that the combination provides a significant therapeutic option for patients with limited treatment alternatives, representing a milestone in precision oncology for kidney cancer.